Pulmonx Corp
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Insider Trading Arrangements
The following discussion includes trading arrangements adopted orterminated by our directors and officers during the three months ended September 30, 2026.
On September 4, 2026, Rich Ferrari, a current member of ourboard of directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 28,246 shares of our common stock. The trading arrangement will expire on September 3, 2027, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms.
On September 10, 2026, Beran Rose, our Chief Commercial Officer, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 132,000 shares of our common stock. The trading arrangement will expire on November 30, 2028, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.